RedHill Biopharma Reports Positive Results in Ebola Virus Study

RedHill Biopharma, a specialty biopharmaceutical company, has announced that its two investigational drugs, opaganib and RHB-107, have shown a "robust" synergistic effect when combined with remdesivir. This exciting development has caused RedHill Biopharma shares to increase by 24% to $1.64.

According to the company, this combination of drugs has significantly improved viral inhibition while also maintaining cell viability during a recent Ebola virus laboratory study funded and conducted by the U.S. Army.

Opaganib, which is administered twice daily, has previously demonstrated positive outcomes in late-stage clinical studies involving patients hospitalized with moderate to severe Covid-19. On the other hand, RHB-107 has successfully completed its Phase 2 study in the United States, meeting its primary endpoint of safety and tolerability. Additionally, it has shown promising efficacy results, including a notable reduction in hospitalization due to Covid-19.

The next phase of research for RHB-107 will involve a 300-patient arm, fully financed by non-dilutive external funding sources such as the U.S. government. The FDA has granted clearance for this phase to begin, and the enrollment of the first patient is expected in the upcoming weeks. The study will take place in multiple countries including the United States, Thailand, Ivory Coast, South Africa, and Uganda. It is estimated to conclude by the end of 2024.